Prasad Suyash
CMO and Head of R&D at TSHA; Senior VP & Chief Med Officer at Audentes Therapeutics, Inc.
- Sold, on record
- $4.1M
- Dollars the filings state
- Form 4 sales
- 11
- Latest Jul 6, 2022
- Form 144 notices
- 0
- Proposed sales
- Companies
- 2
- Filed as an executive or holder
Companies
- TSHATaysha Gene Therapies, Inc.CMO and Head of R&D
- Audentes Therapeutics, Inc.Senior VP & Chief Med Officer
Sales by reason
Form 4 sales per month, last 12 months.
Sales by company
- TSHA142,000 shares
- Audentes Therapeutics, Inc.66,000 shares
Shares sold, every Form 4 sale on record.
Timeline
- 1 Form 4 sale Audentes Therapeutics, Inc.UnusualMar 26 2018
Sold 2,200 shares at $30.00 ($66k)
Prasad Suyash, Senior VP & Chief Med Officer
Sold 100% of holdings ($66k position)0 shares leftFirst sale on recordFiling
- 2 Form 4 sale Audentes Therapeutics, Inc.UnusualJul 2 +98 days
Sold 10,000 shares at $38.41 ($384k)
Prasad Suyash, Senior VP & Chief Med Officer
Sold 100% of holdings ($384k position)0 shares left1.3x usual sizeFiling
- 3 Form 4 sale Audentes Therapeutics, Inc.UnusualOct 1 +91 days
Sold 10,000 shares at $36.88 ($369k)
Prasad Suyash, Senior VP & Chief Med Officer
Sold 100% of holdings ($369k position)0 shares left1.3x usual sizeFiling
- 4 Form 4 sale Audentes Therapeutics, Inc.UnusualFeb 25 +147 days
Sold 10,000 shares at $30.06 ($301k)
Prasad Suyash, Senior VP & Chief Med Officer
Sold 35.4% of holdings ($849k position)18,236 shares left1.3x usual sizeFiling
- 5 Form 4 sale Audentes Therapeutics, Inc.UnusualMay 13 +77 days
Sold 10,000 shares at $36.98 ($370k)
Prasad Suyash, Senior VP & Chief Med Officer
Sold 35.4% of holdings ($1M position)18,236 shares left1x usual sizeFiling
- 6 Form 4 sale TSHAPlan not statedJul 1 +780 days
Sold 79,000 shares at $22.63 ($1.8M)
Prasad Suyash, CMO and Head of R&D
Sold 11.7% of holdings ($15.2M position)593,589 shares leftFirst sale on recordFiling
- 7 Form 4 sale TSHAPlan not statedJul 1 +365 days
Sold 50,139 shares at $3.65 ($183k)
Prasad Suyash, CMO and Head of R&D
Sold 8.4% of holdings ($2.2M position)543,450 shares leftFiling
- 8 Form 4 sale TSHAPlan not statedJul 6 +5 days
Sold 12,861 shares at $3.70 ($48k)
Prasad Suyash, CMO and Head of R&D
Sold 2.4% of holdings ($2M position)530,589 shares leftFiling
Every transaction
Loading transactions…
Sales and notices (11)
| Source | ||||||||
|---|---|---|---|---|---|---|---|---|
| Jul 6, 2022 | TSHA | CMO and Head of R&D | Form 4 sale | 12,861 | $48k | 2.4% | Plan not stated | SEC |
| Jul 1, 2022 | TSHA | CMO and Head of R&D | Form 4 sale | 50,139 | $183k | 8.4% | Plan not stated | SEC |
| Jul 1, 2021 | TSHA | CMO and Head of R&D | Form 4 sale | 79,000 | $1.8M | 11.7% | Plan not stated | SEC |
| May 13, 2019 | Audentes Therapeutics, Inc. | Senior VP & Chief Med Officer | Form 4 sale | 10,000 | $370k | 35.4% | Unusual | SEC |
| Feb 25, 2019 | Audentes Therapeutics, Inc. | Senior VP & Chief Med Officer | Form 4 sale | 10,000 | $301k | 35.4% | Unusual | SEC |
| Oct 1, 2018 | Audentes Therapeutics, Inc. | Senior VP & Chief Med Officer | Form 4 sale | 10,000 | $369k | 100.0% | Unusual | SEC |
| Jul 2, 2018 | Audentes Therapeutics, Inc. | Senior VP & Chief Med Officer | Form 4 sale | 10,000 | $384k | 100.0% | Unusual | SEC |
| Mar 26, 2018 | Audentes Therapeutics, Inc. | Senior VP & Chief Med Officer | Form 4 sale | 2,200 | $66k | 100.0% | Unusual | SEC |
| Dec 1, 2017 | Audentes Therapeutics, Inc. | Senior VP & Chief Med Officer | Form 4 sale | 8,000 | $228k | 100.0% | Unusual | SEC |
| Sep 1, 2017 | Audentes Therapeutics, Inc. | Senior VP & Chief Med Officer | Form 4 sale | 8,000 | $172k | 100.0% | Unusual | SEC |
| Mar 29, 2017 | Audentes Therapeutics, Inc. | Senior VP & Chief Med Officer | Form 4 sale | 7,800 | $234k | 100.0% | Unusual | SEC |